Pushkal Garg Sells 1,548 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Pushkal Garg also recently made the following trade(s):

• On Friday, February 14th, Pushkal Garg sold 1,561 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $255.17, for a total transaction of $398,320.37.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $250.51 on Thursday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a 50 day moving average price of $253.89 and a 200 day moving average price of $263.20. The firm has a market capitalization of $32.43 billion, a price-to-earnings ratio of -115.44 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.94 EPS for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Allworth Financial LP increased its position in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 38 shares in the last quarter. Investment Management Corp of Ontario increased its position in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock worth $1,670,000 after acquiring an additional 40 shares in the last quarter. Nixon Peabody Trust Co. increased its position in shares of Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after acquiring an additional 43 shares in the last quarter. Brevan Howard Capital Management LP increased its position in shares of Alnylam Pharmaceuticals by 3.4% in the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 44 shares in the last quarter. Finally, Huntington National Bank increased its position in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of research analyst reports. Raymond James boosted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Scotiabank reduced their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday, February 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $299.48.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.